Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02363972 · ClinicalTrials.gov registry record · NA

Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD

A NA study of End Stage Renal Disease and End-Stage Kidney Disease, sponsored by Medtronic Endovascular.

Completed
Registry status
NA
Development phase
103
Enrollment target
5
Study locations

NCT02363972 is a NA study of End Stage Renal Disease and End-Stage Kidney Disease that has completed, run by Medtronic Endovascular. The registered enrollment target is 103 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02363972, a NA study of End Stage Renal Disease and End-Stage Kidney Disease, has completed, sponsored by Medtronic Endovascular.

COMPLETED
Registry status
NA
Development phase
103 participants
Enrollment target
5
Study locations

Study Summary

A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.

Interventions

  • DEVICE Ellipsys Vascular Access Catheter

Study Locations (5)

Texas

  • Dallas Nephrology Associates - Plano
  • San Antonio Kidney Disease Center - San Antonio

Arizona

  • Southwest Vascular Center - Tempe

California

  • BNMG San Diego Vascular Access Center - San Diego

Virginia

  • Richmond Vascular Center - North Chesterfield

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2015-02-10
Est. Completion 2016-06
Phase NA

Sponsor

Medtronic Endovascular

25 total trials

What the Registry Record Tells You About NCT02363972

The ClinicalTrials.gov registry entry for NCT02363972 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (88% lower). The listed sponsor is Medtronic Endovascular, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Ellipsys Vascular Access Catheter is the first listed.

NCT02363972 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT02363972 about?

NCT02363972 is a clinical study titled "Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD". A prospective single-arm well-controlled study to evaluate the safety and effectiveness of a less invasive means of establishing vascular access to facilitate dialysis in patients with end stage renal disease.

What is the current status of trial NCT02363972?

This trial is currently completed. It is a NA study. The enrollment target is 103 participants. The study started on 2015-02-10. Estimated completion is 2016-06.

What conditions does trial NCT02363972 study?

This clinical trial studies the following conditions: End Stage Renal Disease, End-Stage Kidney Disease, Fistula, AV Fistula.

What interventions are being tested in trial NCT02363972?

The interventions under investigation include: Ellipsys Vascular Access Catheter (DEVICE).

Who is sponsoring clinical trial NCT02363972?

This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02363972 being conducted?

This trial has 5 study locations across Arizona, California, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for End Stage Renal Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.